The company now offers the patch-based automated insulin delivery (AID) system in Italy, Denmark, Finland, Norway and Sweden. It comes compatible with both the Abbott FreeStyle Libre 2 Plus and Dexcom G6 continuous glucose monitors (CGMs) in those geographies. Omnipod 5 remains the first and only tubeless AID system integrated with both brands of CGMs, the company says.
Insulet integrated Omnipod 5 with FreeStyle Libre 2 Plus in the U.S. in November 2024. The company says that latest integration made Omnipod 5 the most connected tubeless automated insulin delivery system in the U.S. Compatibility in the U.S. came about eight months after the company integrated Omnipod 5 with Libre 2 Plus in Europe. Omnipod 5 already linked with Dexcom CGM, with the companies connecting their latest-generation offerings earlier in 2024.
Insulet’s Omnipod 5 became the first tubeless, wearable automated insulin delivery system cleared for marketing in the U.S. in January 2022. It features SmartAdjust technology that predicts where glucose will be 60 minutes into the future every five minutes. Omnipod 5 then increases, decreases, or pauses insulin delivery based on the user’s desired and customized glucose target.
Acton, Massachusetts–based Insulet touts Omnipod 5 as the number one insulin pump for new users in Europe. It remains the top prescribed AID system in the U.S. and the first tubeless, waterproof AID system with proactive glucose control.
“We are excited to bring our flagship Omnipod 5 AID System to more people across Europe,” said Patrick Crannell, Insulet SVP and International GM. “Following our successful launches of Omnipod 5 in the U.K., Germany, Netherlands, and France, today’s announcement marks another significant step forward to help improve the lives of people with diabetes around the world.”
